South Korea cancels approval of gene therapy Invossa for false reporting of ingredient - (Xinhua via NewsPoints Desk)

  • South Korea has revoked approval of Kolon Life Science's gene therapy Invossa after finding that the country falsely reported the source of an ingredient, Xinhua reported Tuesday.

  • Officials found that an ingredient for the osteoarthritis therapy was derived from kidney cells opposed to cartilage.

  • The country is additionally bringing criminal charges against Kolon for submitting a false document on the drug to regulatory authorities.

  • Officials noted that Invossa was approved in July 2017 after Kolon intentionally concealed possible problems with the drug.

  • The cell used in the treatment can potentially cause cancer.

  • Meanwhile, the drugmaker has denied any concealment and manipulation.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.